Curenetics

NHS Problem

Curenetics’ AI immunotherapy platform addresses the challenge of optimising cancer treatment in the NHS, where nearly 400,000 new cancer cases are diagnosed annually. Immunotherapy, while promising, is costly and not universally effective, leading to trial-and-error treatment approaches. This results in unnecessary expenses and delays in effective care, with treatment costs for some cancers exceeding £100,000 per patient annually. By predicting patient responses to immunotherapy, our AI platform reduces the financial burden on the NHS, and streamlines treatment decisions. It minimises the risk of adverse effects, improving patient outcomes and resource allocation across the healthcare system.

The Solution

Curenetics is revolutionising cancer treatment with AI-powered technology that predicts a patient’s response to immunotherapy.

Impact

Globally, nearly 20 million new cases of cancer are diagnosed each year, with approximately 70 million people living with the disease. Curenetics’ AI test offers a solution by predicting how patients will respond to immunotherapy, helping clinicians optimise treatment decisions, and saving both time and costs in long-term care. This approach also spares patients the physical and emotional toll of enduring ineffective immunotherapy, reducing exposure to toxic side effects and eliminating the prolonged uncertainty of trial-and-error treatments.